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TO THE EDITOR
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder (CMPD) characterized by hyperproliferation of megakaryocytes and persistent thrombocytosis. Thrombosis, bleeding and microvascular occlusive symptoms represent the major cause of morbidity and mortality in ET patients. Thrombocytosis defined as a platelet count higher than 500 ϫ 10 9 /l is a frequent hematological finding in childhood, occuring in 3 to 13% of pediatric patients. 1 Secondary or reactive causes such as infection, trauma or surgery, iron deficiency, hypoesplenism, nonhematologic malignancies or rebound from chemotherapy, represent the etiology of most cases. In contrast, ET is extremely rare at the pediatric age, 2 although at present, with the advent of automated platelet counting, it is being diagnosed with increasing frequency at a younger age. To date no more than 50 pediatric cases of ET have been reported. [1] [2] [3] Familial occurrence is observed in 40-55% of all childhood cases with primary thrombocytosis, and these patients characteristically show neither thrombotic manifestations nor malignant or myelofibrotic transformation during their clinical follow-up. 2 ET is currently diagnosed through exclusion of non-ET CMPD and conditions associated with reactive thrombocytosis by criteria set by the Polycythemia Vera Study Group (PVSG). 4 A diagnosis of ET in the individual pediatric patient is a matter of great significance given the known prognostic (thrombohemorrhagic complications, and clonal evolution) and therapeutic implications of this CMPD.
Hemopoietic progenitors have attracted attention because some adult patients with ET and other CMPD show endogenous growth. 5 The characteristic pattern of endogenous growth is based on the ability of colony formation in the absence of a stimulating agent in the culture medium. This phenomenon is not observed in either normal subjects or in RT. 5, 6 To our knowledge, in pediatric ET there is no information about in vitro cultures of megakaryocytic progenitors (CFU-MK) and it is scanty in erythroid (BFU-E) and granulomonocytic progenitors (CFU-GM). 3 We report the results of in vitro cultures of circulating myeloid progenitor cells (BFU-E, CFU-MK and CFU-GM) in five pediatric patients, observed in four institutions over the last 15 years, diagnosed as ET according to the PVSG criteria. 4 The main clinical and laboratory data of our patients at diagnosis are given in Table 1 .
The results of cultures in vitro of circulating myeloid progenitor cells from the five patients and our control values 5 are given in Table 2 . Positive criteria suggested for distinguishing ET from patients with reactive thrombocytosis have included, among others, endogenous or spontaneous erythroid and/or megakaryocytic progenitor growth from peripheral blood. This cytokine independent, or at least hypersensitive colony growth has been demonstrated as a characteristic finding in adult ET patients, 5, 7 and has been included as a criterion of the revised diagnostic criteria of ET. 6 In our experience, four out of five pediatric patients without familial history of thrombocytosis showed endogenous BFU-E and CFU-MK growth. Spontaneous CFU-GM colony formation was not observed in any patient. The number of progenitors, either BFU-E, CFU-MK or CFU-GM, was higher than control values. There is only one previous report about progenitor colony formation in pediatric patients with ET. Randi et al, 3 in a clinical report of five children, described none of their patients as having spontaneous BFU-E formation. Our results disagree with those of Randi et al 3 ocytic and granulomonocytic colony formation has not previously been reported in childhood ET, and for this reason, we cannot compare our results with other investigators' experience. Moreover, it is noteworthy that the percentage (80%) of our cases that showed spontaneous BFU-E and/or CFU-MK colony growth is similar (91.6%) to our results in adult ET patients. 5 The BFU-E and/or CFU-MK endogenous growth and lack of endogenous growth of CFU-GM, observed in the greater part of adult and pediatric ET patients, demonstrate that alterations can be found at least in two different cell lineages (erythroid and megakaryocytic) or in a bipotent erythro-megakaryocytic progenitor. 8 The alteration of the in vitro growth of both classes of erythroid and megakaryocyte progenitors in ET patients is probably the result of an imbalance in their sensitivity to growth and to inhibiting factors. This alteration could play an important role in ET and suggests that the target cells of the neoplastic transformation in ET escape from the control of physiological regulatory mechanisms.
The diagnosis of ET remains one of exclusion, and in the absence of clinical and hematological abnormalities suggestive of CMPD, the major challenge is usually to exclude a reactive thrombocytosis (RT). 4 The distinction between ET and secondary thrombocytosis is clinically relevant because hemostatic complications in ET can be unpredictable and even life-threatening.
In conclusion, in our experience endogenous erythroid and/or megakaryocytic colony growth from peripheral blood is a frequent and characteristic finding in non-familial ET pediatric patients and this type of progenitor growth should be considered a positive criteria for the diagnosis of ET in childhood. 
The human leukemic U937 cell line has been widely used to study neoplasia, cancer therapeutics, cell differentiation, and HIV infections. It has been previously found by limiting dilution cloning that some U937 subclones (plus clones) support HIV replication efficiently and some (minus clones) do not. 1 Based on the more mature phenotype of the minus clones and observations that telomerase activity declines during cell maturation in humans 2 we hypothesized that they are in a more 'differentiated' state than the plus clones and therefore their telomerase activity would be lower than that of the plus cells. Here, we report the striking difference between plus and minus U937 clones in their telomerase activity, telomere length, apoptosis, growth rate and gene expression, but similarity in the rate of their division as measured by BrdU incorporation (Tables 1 and 2 and cell division in these cells, a potential role for Ets1 and Ets2 in telomerase activity regulation, and the existence of another yet to be identified pathway(s) of Id2 and telomerase regulation, which is currently under investigation. Thus minus and plus clones could be used as a model system to study regulation of telomerase and other differentiation-related genes in leukemic cells, and their gene expression profiling could help in elucidation of the role of telomerase and other cancer-related genes for progression of cancer in leukemias.
In an attempt to elucidate the mechanism of differential telomerase activity regulation in the two subclones we evaluated the role of cMyc/Mad1 by Western blotting and RT PCR. We found positive correlation of telomerase activity with c-Myc/Max expression and negative with Mad1 (Table 1) . Furthermore, differentiation agents modulating c-Myc level altered telomerase activity in a parallel fashion, suggesting a role for the c-Myc pathway in telomerase regulation (data not shown). This is in agreement with data for HL60 cells 3 demonstrating the importance of the c-Myc/Max/Mad1 interplay for telomerase regulation in leukemia cell lines.
To find other genes that are differentially expressed in the minus and plus clones, and may have a role in the regulation of cell growth and telomerase activity, we measured the gene expression profiles of minus and plus clones. The samples were duplicated and only those 684 genes that have statistically significant differences (t-test, P Ͻ 0.05) and positive calls (P following the Affymetrix notation for
